Page 24 - Read Online
P. 24

Ballestri et al. Metab Target Organ Damage 2023;3:1  https://dx.doi.org/10.20517/mtod.2022.23  Page 13 of 22



 Table 4. Association between liver fibrosis assessed by elastographic techniques and cardiovascular outcomes/mortality

 Author   F-up   CVD/mortality                                Clinical variables
 (ref.)  Study characteristics  (year)  NAFLD (%) Fibrosis (%)  Outcomes (%)  Main findings at MVA  for adjustment/covariates
 Cross-sectional

 Friedrich-  505 consecutive patients   -  71.5% (CAP ≥  11.2% NAFLD with   70.5%   High-grade CAD is independently predicted by   Sex, hypertension, and hip-waist-
 [94]
 Rust et al.  undergoing elective coronary   234 dB/m)  advanced LF (VCTE   CHD 3 (stenosis  ≥   NAFLD but not NAFLD with advanced LF  ratio
 angiography for various   LSM ≥ 7.9kPa)  75%)
 indications, 78.2% men, mean
 age 65.7 years
 [95]
 Song et al.  120 consecutive patients with   -  67% in non-  2DSWE-SSI (kPa) 4.82  50%   LSM (by 2D-SWE SSI), age, male sex, total   T2D, hypertension, smoking, HDL-C,
 suspect CHD submitted to   CHD,   ± 0.92 in non-CHD vs.   CHD  cholesterol, and visceral fat thickness were   LDL-C, HbA1c,
 coronary angiography or CTA   95% in CHD  6.37 ± 1.39 in CHD  determinants of CHD  NAFLD
 (n.60 CHD and n.60 non-CHD)
 Lombardi   394 T2D outpatients from 5   -  89% (US)   21% significant LF   19% CVD (prior MI   Significant LF was independently associated with  Age, sex, smoking, cardiometabolic
 [96]
 et al.  diabetes centers, 52% men,   72% (CAP ≥   (VCTE LSM ≥ 7.0/6.2   and/or IS), 33%   prior CVD (OR 3.3) and the presence of   risk factors, diabetes-related
 mean age 68 ± 10 years  248 dB/m)  kPa by M/XL probe)  microvascular   microvascular complications (OR 4.2), mainly   variables, severe US steatosis
 complications    CKD (OR 3.6) and retinopathy (OR 3.7)
 Mantovani   137 consecutive patients with   -  73.7% (US)  17.5% (VCTE LSM ≥ 7   20.4% CV   CV complications (previous CHD, IS, permanent  Age, sex, cardiometabolic risk
 [97]
 et al.  non-insulin-treated T2D,   kPa) or 10.2%   complications (medical  AF) increased across LSM tertiles (from around   factors, diabetes-related variables,
 52.8% women, mean age 69.9   (LSM ≥ 8.7 kPa)   history)  15% to 30%). At MVA, LSM tertile 3 remained   CRP levels
 ± 7 years  significant LF  significantly associated with an increased risk of
                  prevalent CKD but not with cardiovascular
                  complications

 Mikolasevic  442 outpatients with   -  84.2% (CAP  46.6% significant LF   25% macrovascular   Significant LF but not steatosis was   Age, sex, cardiometabolic risk
 [98]
 et al.  established T2D, 52.7%   ≥ 238 dB/m)  (VCTE LSM ≥ 7.0/6.2   complications (MI, IS)   independently associated with MI (OR 6.61),   factors, diabetes-related variables,
 women, median (IQR) age 62   kPa by M/XL probe)  (at least one) (medical   peripheral polyneuropathy (OR 4.55), CKD (OR   CRP levels
 (53-68) years  history)  4.54), and retinopathy (OR 1.81)
 [99]
 Long et al.  3276 Framingham Heart Study  -  28.8%   8.8% significant LF   -  LF was associated with multiple CVD risk factors  Age, sex, smoking, alcohol, physical
 adult participants, 54%   (CAP ≥ 290   (VCTE LSM ≥ 8.2 kPa)  (obesity: OR 1.82; MetS: OR 1.49; diabetes: OR   activity, aminotransferases, and CAP
 women, mean age 54 ± 9 years  dB/m)  2.67, hypertension: OR 1.52; low HDL-C: OR
                  1.47)
 Pennisi   542 subjects from a   -  31.7% (CAP >  4.8% severe LF (VCTE   22.2% high-risk ASCVD  Both steatosis (OR 1.62, 95%CI: 1.13-2.33) and   Age, BMI
 [100]
 et al.  community-based study, 59%   288 dB/m)  LSM ≥ 9.6/9.3 kPa by   score  severity of
 women, mean age of 58 ± 10   M/XL probe)  fibrosis (OR 1.67, 95%CI: 1.18-2.36) were
 years            independently associated with higher ASCVD
 [101]
 Park et al.  105 patients with NAFLD, 52%  -  100% (MRI-  35.2% significant LF   49.5% CAC > 0  LS was independently associated with the   Age, sex, smoking, total cholesterol,
 women, mean age of 55 years  PDFF ≥ 5%)  (MRE ≥ 2.97 kPa)  presence of CAC in a sex and age-adjusted   HDL-C, SBP, medication for
                  model (OR 2.23; 95%CI: 1.31-4.34) as well as in   hypertension, T2D, and history of
                  an FRS-adjusted model (OR 2.16, 95%CI: 1.29-  CVD
                  4.09)
 Ciardullo   2734 subjects from NHANES   -  48.6% (CAP  9.7% significant LF   12%   Neither steatosis nor significant fibrosis was   Age, sex, race-ethnicity, BMI, T2D,
 [102]
 et al.  2017-2018, 53% women, mean   ≥ 274 dB/m) (VCTE LSM ≥ 8 kPa)  (9% CHD)  independently associated with CVD  smoking, CKD
 age 59 years
   19   20   21   22   23   24   25   26   27   28   29